SCHEMBL1011783

SCHEMBL1011783

CC(C(=O)O)c1cnc(Cc2ccc(NC(=O)OCc3ccc(F)cc3)cc2)nc1N(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MGLL Q99685 1/20 0.40
AKT3 Q9Y243 1/20 0.39
TBXA2R P21731 1/20 0.39
PTGDR Q13258 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
ADORA3 P0DMS8 2/20 0.39
ADORA2A P29274 2/20 0.39
ADORA2B P29275 2/20 0.39
ADORA1 P30542 2/20 0.39
OPRK1 P41145 1/20 0.38
ROCK2 O75116 1/20 0.38
CXCR1 P25024 1/20 0.38
CXCR2 P25025 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1010687 0.93 ROCK2 (0.46) SMN1; SMN2MGLLPTGDR2ROCK2POLB
SCHEMBL1010059 0.84 MEN1 (0.47) KMT2AMEN1SMN1; SMN2L3MBTL1MGLL
SCHEMBL1010767 0.82 ALDH1A1 (0.48) KMT2AMEN1
SCHEMBL1010810 0.82 MEN1 (0.47) KMT2AMEN1SMN1; SMN2L3MBTL1MGLL
SCHEMBL15746542 0.77 PTGDR2 (0.45) KMT2AMEN1SMN1; SMN2L3MBTL1TBXA2R
SCHEMBL5961340 0.77 MEN1 (0.52) KMT2AMEN1SMN1; SMN2L3MBTL1MGLL
SCHEMBL1008677 0.77 PTGDR2 (0.47) TBXA2RPTGDRPTGDR2ROCK2POLB
SCHEMBL27655918 0.76 POLB (0.43) KMT2APTGDR2ROCK2CYP2C19POLB
SCHEMBL1010809 0.76 MEN1 (0.48) KMT2AMEN1SMN1; SMN2L3MBTL1MGLL
SCHEMBL27634906 0.76 POLB (0.45) SMN1; SMN2MGLLPTGDR2ROCK2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960393-B2 Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 ACTIMIS PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
EP-1633726-B1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 ACTIMIS PHARMACEUTICALS INC (US) 2011-01-05 EP disclosed